Kenvue Inc., the consumer health business of Johnson & Johnson, climbed from its initial public offering price during Thursday’s debut session — breaking a lull in large US listings that’s lasted for more than a year.
The maker of brands including Tylenol, Band-Aid, Listerine and Nicorette rose 22% from the $22 offering price in its first day of trading. Kenvue’s $3.8 billion IPO was the biggest in New York since Rivian Automotive Inc. in November 2021 due to five quarters of volatility and interest-rate uncertainty that stalled most deals in the pipeline.
The IPO valued Kenvue at about $42 billion, according to Bloomberg Intelligence analyst Diana Gomes. Kenvue marketed the shares at $20 to $23 through a syndicate led by Goldman Sachs Group Inc., JPMorgan Chase & Co. and Bank of America Corp.
Source: CA.Finance
Omni Talk is the retail blog for retailers, written by retailers. Chris Walton and Anne Mezzenga founded Omni Talk in 2017 and have quickly turned it into one of the fastest growing blogs in retail. 